KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Evolent Health (EVH) Revenue (2016 - 2025)

Historic Revenue for Evolent Health (EVH) over the last 11 years, with Q3 2025 value amounting to $479.5 million.

  • Evolent Health's Revenue fell 2283.03% to $479.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.1 billion, marking a year-over-year decrease of 1664.61%. This contributed to the annual value of $2.6 billion for FY2024, which is 3008.54% up from last year.
  • Latest data reveals that Evolent Health reported Revenue of $479.5 million as of Q3 2025, which was down 2283.03% from $444.3 million recorded in Q2 2025.
  • In the past 5 years, Evolent Health's Revenue registered a high of $647.1 million during Q2 2024, and its lowest value of $215.1 million during Q1 2021.
  • In the last 5 years, Evolent Health's Revenue had a median value of $444.3 million in 2025 and averaged $430.8 million.
  • In the last 5 years, Evolent Health's Revenue skyrocketed by 5848.58% in 2022 and then crashed by 3134.03% in 2025.
  • Quarter analysis of 5 years shows Evolent Health's Revenue stood at $248.4 million in 2021, then skyrocketed by 53.98% to $382.4 million in 2022, then surged by 45.4% to $556.1 million in 2023, then rose by 16.27% to $646.5 million in 2024, then fell by 25.83% to $479.5 million in 2025.
  • Its Revenue was $479.5 million in Q3 2025, compared to $444.3 million in Q2 2025 and $483.6 million in Q1 2025.